We read with interest the article by Walton et al. about a self-controlled case series
using national hospitalisation and immunisation records about the incidence of venous
and arterial thrombosis among 6039 vaccinees hospitalised for thrombosis within three
weeks following vaccination with the BNT162b2 vaccine in New Zealand during an observational
period from 19th February 2021 through 19th February 2022 [
[1]
]. It was found that 5127 vaccinees had venous thromboembolism, 605 arterial thrombosis,
272 splanchnic thrombosis, and 35 venous sinus thrombosis, which was not different
from an appropriate control group [
[1]
]. The study is appealing but carries limitations that raise concerns and should be
discussed.Keywords
Abbreviations:
BNT162b2 (Biontech Pfizer vaccine)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Thrombotic events following the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) in aotearoa New Zealand: a self-controlled case series study.Thromb. Res. 2022 Dec; 28: 102-108https://doi.org/10.1016/j.thromres.2022.12.012
- Clinical profile and risk factors of cerebral venous sinus thrombosis (CVST) in Sudan: a multicenter cross-sectional study.Ann. Med. Surg. (Lond.). 2022 Nov 17; 84104891https://doi.org/10.1016/j.amsu.2022.104891
Article info
Publication history
Published online: February 03, 2023
Accepted:
January 26,
2023
Received:
January 16,
2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Ltd. All rights reserved.
